69 Review of outcomes at a tertiary cancer centre of procarbazine (third line) and etoposide (fourth line) chemotherapy for recurrent gliomas

Clicks: 18
ID: 326699
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #160 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction There is no standard recommended third- or fourth-line chemotherapy treatment for patients with recurrent gliomas. At our tertiary cancer centre, CCNU, procarbazine and etoposide are commonly used sequentially as second-, third- and fourth-line treatments. This review assessed progression free survival (PFS), overall survival (OS) and tolerability of single agent procarbazine and etoposide chemotherapy. Methods All patients coded glioma, WHO grade 2 – 4, who commenced third line procarbazine or fourth line etoposide between 1st November 2016 and 31st December 2024 were identified. 94 patients were analysed for procarbazine and 21 patients for etoposide. Age range 23 – 77y. Treatment-related toxicity was reviewed. Data analysis was performed June 2025 with SPSS for survival. Results For the 94 patients commencing procarbazine, duration of treatment was mean 84 days, median 68 days with a maximum duration of 453 days. The mean PFS was 4.2 months, median 3 months. 6 months PFS was 10%. The mean OS was 10 months with a median 6 months. 12 months OS was 19.8%. For the 21 patients commencing etoposide, duration of treatment was a mean 141 days, median 80 days with a maximum duration of 1127 days. Mean PFS was 5 months, median 3 months. 6 months PFS was 18%. The mean OS was 16 months, median OS 7 months. 12 months OS was 40%. 6 patients discontinued treatment due to toxicity, mainly thrombocytopaenia or fatigue. Dietary restrictions were well tolerated. Conclusions Procarbazine and etoposide were generally stopped after 3 cycles, reflecting progression on first MRI. Median OS following procarbazine was 6 months and following etoposide was 7 months. However, a few patients responded exceptionally well. Chemotherapy was well tolerated, with few discontinuing due to toxicity.
Reference Key
openalex_W7204446035 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chloë May, Victoria Yu, Stephanie Thomas, Helen Wong, Shaveta Mehta, Aditya Shenoy
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.089
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.089/70805887/noag172.089.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.